Education
About Us
Working with TipRanks
Follow Us
Flynn James P Insider Profile
4 Followers
Flynn James P, Director at Oruka Therapeutics, holds ― shares in Oruka Therapeutics (Ticker: ORKA), holds 17.90K shares in Lite Strategy (Ticker: LITS), holds 15.00K shares in Synlogic (Ticker: SYBX). Most recently, Flynn James P ― shares of Oruka Therapeutics on ― for an estimated value of ―.
Flynn James P has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Flynn James P holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Flynn James P
Flynn James P's Trading History
Oruka Therapeutics
―
Director
―
―
Lite Strategy
Oct 02, 2025
Director
Uninformative Buy
25.40K
$34.91K
Synlogic
Apr 29, 2025
Director
Uninformative Buy
―
$25.65K
List of latest transactions for each holding click on a transaction to see Flynn James P's performance on stock
You May Also Like
Flynn James P insider profile FAQ
What is the percentage of profitable transactions made by Flynn James P?
The percentage of profitable transactions made by Flynn James P is ―.
What is the average return per transaction made by Flynn James P?
The average return per transaction made by Flynn James P is ―.
What stocks does Flynn James P hold?
Flynn James P holds: ORKA, LITS, SYBX stocks.
What was Flynn James P’s latest transaction?
Flynn James P latest transaction was an Uninformative Buy of ―.
What was Flynn James P's most profitable transaction?
Flynn James P’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Flynn James P's role in Oruka Therapeutics?
Flynn James P's role in Oruka Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.